Imugene names new advisory board members
This article was originally published in Scrip
Australian biopharmaceutical company Imugene, which develops oncology drugs, has appointed Professor Dr Christoph Zielinski and Professor Dr Ursula Wiedermann to its scientific advisory board. Professor Zielinski is the director of the clinical division of oncology and chair of the department of medicine at the Medical University of Vienna, Austria. He is also coordinator of the comprehensive cancer centre at the university and the General Hospital in Vienna and is president of the Central European Cooperative Oncology Group (CECOG). Meanwhile, Professor Wiedermann is professor of vaccinology and head of the institute of specific prophylaxis and tropical medicine of the Medical University Vienna.